Exclusion from prescription according to § 92 (1) SGB V

The G-BA has so far applied the possibility of exclusion from prescription according to § 92 (1) SGB V only in select cases

Log in to read more ...

The AMNOG monitor is a subscription-based service for pharmaceutical manufacturers and institutions. Enter your account details here in order to analyse the results of the early benefit assessment in Germany – or contact us for more information.